Axitinib
- PDF / 169,636 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 8 Downloads / 161 Views
1 S
Various toxicities: 3 case reports In a retrospective study of 10 patients with advanced renal cell carcinoma (treated at Peking University Cancer Hospital & Institute, China between April 2019 and December 2019), three patients [ages and sexes not stated] were described, who developed loss of appetite, elevated transaminase levels, nausea, fatigue or elevated adrenocorticotrophic hormone during treatment with axitinib for advanced renal cell carcinoma. The patients, who had advanced renal cell carcinoma, started receiving treatment with oral axitinib 5mg twice daily with concomitant administration of sintilimab. Subsequently, the patients developed axitinib-related adverse reactions manifested as grade III/IV loss of appetite (1 patient), grade III/IV elevated transaminase levels (1 patient) and nausea, fatigue and grade III/IV elevated adrenocorticotrophic hormone (ACTH) [1 patient; times to reactions onsets not stated]. Hence, axitinib dose was reduced to 5mg once daily in one patient, who had a loss of appetite. Treatment with axitinib was stopped in the remaining two patients. Simultaneously, one of these patients received unspecified hepatoprotective treatment, which resulted in normalisation of the transaminase level. The remaining two patients received unspecified symptomatic treatment, which resulted in the improvement of symptoms. Du Y, et al. Efficacy of axitinib plus sintilimab in intermediate-and high-risk advanced renal cell carcinoma. [Chinese]. Chinese Journal of Clinical Oncology 47: 513-516, No. 803516358 10, 2020. Available from: URL: http://doi.org/10.3969/j.issn.1000-8179.2020.10.342 [Chinese; summarised from a translation]
0114-9954/20/1831-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 21 Nov 2020 No. 1831
Data Loading...
